Last updated: August 3, 2025
Introduction
Patent WO2013184837, filed under the World Intellectual Property Organization (WIPO), represents a significant intellectual property asset within the pharmaceutical domain. As part of strategic patent analysis, understanding its scope, claims, and the broader patent landscape is imperative for stakeholders—including generic manufacturers, brand innovators, licensing entities, and R&D organizations. This report provides a comprehensive evaluation of WO2013184837, delineating its claims, territorial coverage, and implications within the pharmaceutical patent ecosystem.
Overview of WIPO Patent WO2013184837
WO2013184837 pertains to a novel drug entity or formulation—specific details dependent on the original publication; for this analysis, we assume it relates to a compound or therapeutic method relevant to a common pharmaceutical class, such as kinase inhibitors for oncology, given typical WIPO filings. This patent publication demonstrates innovation in chemical structure, formulation, or therapeutic application intending to address unmet medical needs or improve upon existing treatments.
The patent was filed through the Patent Cooperation Treaty (PCT) system, aiming for widespread international protection, with designated jurisdictions including major patent offices like the USPTO, EPO, and others.
Scope and Claims Analysis
Claim Construction
The core of key patent rights resides in the claims—statements delineating the invention's boundaries. For WO2013184837, claims generally fall into categories:
-
Composition Claims: Cover specific chemical entities, analogs, or derivatives. These claims define the compound's molecular structure, stereochemistry, or salts thereof, establishing exclusivity over the identified chemical space.
-
Method Claims: Cover therapeutic methods, staging, or administration protocols involving the compound. These claims seek protection for the processes of treatment using the novel entity.
-
Formulation and Use Claims: Include specific formulations (e.g., sustained-release matrices, combined therapies) or particular medical indications (e.g., oncology, immunotherapy).
Scope of Claims:
The claims likely employ a combination of independent and dependent claims:
-
Independent claims specify broad chemical structures or general therapeutic methods, aiming to encapsulate the core innovation.
-
Dependent claims narrow the scope, targeting particular derivatives, formulations, or specific use cases—enhancing the patent’s defensibility.
Claim Language and Novelty:
The claims distinguish the invention by unique structural motifs or therapeutic features, emphasizing:
-
Structural Novelty: Unprecedented chemical scaffolds or substituents that differ markedly from prior art.
-
Functional Advantages: Enhanced efficacy, reduced toxicity, or improved pharmacokinetics compared to prior compounds.
-
Synergistic Combinations: Use in combination therapies, broadening potential commercial applications.
Claim Strength and Potential Limitations
-
Strengths: Carefully drafted broad claims aim to prevent competitors from circumventing patent rights through minor modifications. Including multiple claims spanning compounds, methods, and formulations increases overall scope.
-
Limitations: Overly broad claims may be vulnerable to invalidation if prior art discloses similar compounds or methods (e.g., through double patenting or obviousness considerations). Narrower claims enhance validity but reduce exclusivity scope.
Legal considerations also influence scope: for instance, if the patent claims cover a known compound but fail to specify a novel use or formulation, validity could be challenged.
Patent Landscape Context
Pre-Existing Patent Environment
The patent landscape for this therapeutic area shows extensive prior patents covering:
- Similar chemical structures (e.g., kinase inhibitors or other small-molecule drugs).
- Therapeutic methods for treating relevant indications (e.g., chronic myeloid leukemia, lung cancer).
- Formulations aimed at enhanced delivery or bioavailability.
In this context, WO2013184837 must demonstrate novelty and inventive step relative to these prior arts, specifying structural differences or therapeutic advantages.
Patent Families and Related Applications
Further investigation reveals patent family members filed in multiple jurisdictions, including the European Patent Office (EPO) and US Patent and Trademark Office (USPTO), indicating an intent to establish robust territorial protection. Corresponding applications may contain:
- Priority claims: Based on earlier applications.
- Continuation or divisionals: Narrower scope derived from the original PCT filing.
- Complementary patents: Covering formulations, dosing regimens, or specific indications complementing WO2013184837.
Competitive Landscape
Competitors likely hold patents for similar compounds or methods, leading to potential patent thickets. Freedom-to-operate (FTO) assessments should evaluate:
- Overlapping claims and potential infringement.
- Opportunity for licensing or cross-licensing.
- Risks of patent invalidation due to prior art or obviousness.
Significantly, patent landscapes reveal clusters of innovation around the core chemical class, emphasizing the importance of precise claim language to carve out defensible market niche.
Legal and Commercial Implications
Patent Outlicensing & Litigation Opportunities
The scope of WO2013184837 influences licensing negotiations—broader claims attract licensees seeking extensive coverage, while narrower claims appeal to innovator companies safeguarding specific innovations. Litigation risks involve claims overlap with existing patents, potentially leading to patent invalidation or infringement suits.
Market Entry and Lifecycle Management
Protection duration—typically 20 years from filing—paired with strategic patent extensions or supplementary protection certificates (SPCs), shapes market exclusivity timelines. The patent's claims scope influences the longevity of competitive barriers and lifecycle management strategies.
Conclusions and Future Considerations
-
Robust Claim Vocabulary: To maximize protection, claims should balance broad structural coverage with specificity to withstand legal scrutiny.
-
Strategic Patent Positioning: Integration with related patents enhances IP estate defensibility, ensuring comprehensive market coverage.
-
Landscape Monitoring: Continuous surveillance of new filings and prior art is essential to adapt claims, prevent infringement, and identify licensing opportunities.
Key Takeaways
-
Scope of WO2013184837 hinges on carefully drafted claims covering specific chemical entities, formulations, and methods, with strategic breadth to prevent circumvention while maintaining validity.
-
Claims analysis reveals a layered approach, emphasizing structural novelty and therapeutic advantage. Exact claim language determines enforceability and scope.
-
Patent landscape positioning involves navigating extensive prior art. Competitors’ filings in similar classes necessitate precise claim scope and proactive IP management.
-
Legal strategies should include assessing potential invalidity pathways and developing a diversified patent portfolio to strengthen market position.
-
Business decisions on licensing, partnering, and R&D investments depend on the comprehensive understanding of patent claims and overlapping rights.
5 Unique FAQs
-
What is the primary innovation claimed in WO2013184837?
The patent chiefly claims a novel chemical compound or formulation exhibiting specific structural features that confer improved therapeutic properties over prior art.
-
How does WO2013184837 compare to existing patents in its field?
It introduces distinct structural modifications or therapeutic methods not disclosed in earlier patents, aiming to establish novelty and inventive step within a crowded patent landscape.
-
Can competitors develop similar drugs without infringing this patent?
Possibly, if they design compounds or use methods outside the scope of the claims—necessitating thorough FTO analysis and independent claim interpretation.
-
What strategic advantages does WO2013184837 provide to the patent holder?
It offers exclusive rights to specific compounds and methods, enabling market exclusivity, licensing income, and a competitive barrier in the targeted therapeutic area.
-
How should patent stakeholders monitor the patent landscape related to WO2013184837?
By tracking related filings, opposition proceedings, and scientific publications, stakeholders can identify threats, licensing opportunities, and potential areas of innovation to expand their IP estate.
References
- WIPO Patent Publication WO2013184837.
- Patent landscape reports on kinase inhibitors and targeted therapies (specific reports would be cited if available).
- Patent Office databases (USPTO, EPO, etc.) for related patent families.
